Susanna Proudman

Sep 3, 2024 | acrjournals.onlinelibrary.wiley.com | Laura Ross |Melbourne Victoria |Dylan Hansen |Susanna Proudman

Supporting Information Filename Description acr25427-sup-0001-Disclosureform.pdfPDF document, 687.5 KB Disclosure Form acr25427-sup-0002-supinfo.docxWord 2007 document , 54.2 KB Supporting Information

Jun 27, 2024 | acrjournals.onlinelibrary.wiley.com | Laura Ross |Dylan Hansen |Susanna Proudman |Rheumatology Unit

Supporting Information Filename Description art42939-sup-0001-Disclosureform.pdfPDF document, 368.6 KB Disclosure Form art42939-sup-0002-Supinfo.docxWord 2007 document , 152.9 KB Appendix S1: Supporting Information

Jun 20, 2024 | digitalcommons.library.tmc.edu | Jessica Fairley |Dylan Hansen |Laura Ross |Susanna Proudman

To describe the clinical phenotype and prognosis of people in the Australian Scleroderma (SSc) Cohort Study with pulmonary arterial hypertension (PAH) with or without interstitial lung disease (ILD). Participants meeting ACR/EULAR criteria for SSc were divided into four mutually exclusive groups: those meeting criteria for PAH (PAH-only), ILD (ILD-only), concurrent PAH and ILD (PAH-ILD) or neither PAH nor ILD (SSc-only).

May 13, 2023 | arthritis-research.biomedcentral.com | Jessica Fairley |Dylan Hansen |Laura Ross |Susanna Proudman |Joanne Sahhar |Gene-Siew Ngian | +9 more

ParticipantsParticipants were recruited from the ASCS, a multicentre Australian study of SSc. The ASCS has been approved by all Human Research Ethics Committees of participating sites. Written informed consent was obtained from all participants prior to the collection of any study data. This study is conducted in accordance with the Declaration of Helsinki.